Pfizer Inc (PFE)

[DewDiligence]

PFE presents Etrasimod datasets from two phase-3 trials in second-line UC:

https://finance.yahoo.com/news/pfizer-presents-elevate-pivotal-findings-104500206.html

Both Phase 3, multi-center, randomized, placebo-controlled trials achieved all primary and key secondary endpoints, with etrasimod demonstrating a safety profile consistent with previous studies.

In the 52-week ELEVATE UC 52 study, clinical remission was 27.0% for patients receiving etrasimod compared to 7.4% for patients receiving placebo at week 12 (19.8% differential, P=?.001) and was 32.1% compared to 6.7% at week 52 (25.4% differential, P=?.001).

In the 12-week ELEVATE UC 12 study, clinical remission was achieved among 24.8% of patients receiving etrasimod compared to 15.2% of patients receiving placebo (9.7% differential, P=.0264).

PFE previously reported that these trials were successes (#msg-168367673, #msg-168301477), but today’s announcement is the first look at the details.

Etrasimod is the main asset PFE obtained in the ARNA buyout (#msg-167099213). Etrasimod is an S1P receptor modulator, the same MoA as BMY’s Zeposia.